Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

NRx Pharmaceuticals (NASDAQ: NRXP) , via its wholly owned subsidiary HOPE Therapeutics(TM), Inc., has signed a binding Letter of Intent to acquire a ...

NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owned subsidiary HOPE Therapeutics (TM), Inc., has signed a binding Letter ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...